相关实验视频

Updated: Jul 10, 2026

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

使用西利比宁纳米脂酶缓解乙氨基诱导的肝衰竭:一个体内研究

Fatemeh Gheybi¹, Alireza Khooei², Azam Hoseinian²

¹Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Biochemical and biophysical research communications

|July 28, 2023

概括

西利马林纳米体通过减少有毒代谢物和保持肝功能,有效地保护免受乙氨基诱导的肝损伤. 这种新型的输送系统显示出显著的肝保护作用,特别是通过腹腔内输送.

科学领域:

药理学药理学是指药理学的学科.
纳米技术纳米技术
肝病学肝病学是一种肝病学.

背景情况:

过量服用乙氨基会通过消耗GSH和增加ROS引起肝功能衰竭.
氨酸 (SLB) 具有抗氧化特性,但其生物可用性较差.
纳米脂质体提供了一个潜在的解决方案,以提高SLB的治疗疗效.

研究的目的:

开发和评价西利比宁 (SLB) 脂质体,用于对抗乙氨基引起的急性肝毒性.
使用纳米脂质体配方提高SLB加载效率和生物可用性.
评估SLB纳米脂质体的肝保护作用和安全性.

主要方法:

使用脂膜方法制备了带有SLB的纳米脂质体.
描述包括DLS,TEM,释放研究和体外细胞毒性测试.
在体内有效性被评估在一个乙氨基诱导的肝毒性小鼠模型,评估肝酶 (ALT,AST,ALP).

主要成果:

SLB纳米体表现出均的球形形态 (115 nm) 具有高的SLB捕获率 (约. 40%). 在这个问题上.
纳米脂质体表现出有利的释放动力学,并且对NIH3T3细胞无毒.
在小鼠中,SLB纳米脂酶显著降低了血清ALT,AST和ALP水平,表明肝功能得到保护.

结论:

SLB纳米脂质体具有显著的肝保护作用,可以防止乙胺引起的肝损伤.
在降低ALT水平方面,SLB纳米脂质体的内注射比N-乙半氨酸更有效.
该研究强调了SLB纳米脂质体作为对乙氨基毒性的治疗策略的潜力.

关键词:

乙氨基毒性毒性乙氨基毒性脂质细胞体中的脂肪体.肝脏肝脏肝脏肝脏这里是Silibinin和Silibinin.转氨基酶是一种转氨基酶.

更多相关视频

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...